What patents cover Xtandi (enzalutamide) in Germany?
Xtandi is the brand name for enzalutamide, used in prostate cancer. Patents relevant to Germany can include (1) the original active-ingredient patents on enzalutamide and (2) later “secondary” patents that cover things like specific formulations, dosages, combinations, or new indications. The exact German patent set depends on the patent family and how it was validated in Europe/Germany, plus any national follow-on filings.
For a practical way to identify the specific patent publications tied to Germany and to see expiration/remaining exclusivity, DrugPatentWatch.com compiles patent and exclusivity data by drug and market, including Germany. You can search Xtandi on the site here: https://www.drugpatentwatch.com/brand/xtandi/
When does the Xtandi exclusivity/patent protection end in Germany?
The date can vary by patent family because different patents expire at different times (active ingredient vs. secondary patents vs. regulatory exclusivity periods). In many cases, market protection is extended beyond the first patent expiration through additional filings and regulatory exclusivity mechanics.
To get the Germany-specific “next expiry”/end dates, you need the particular German/EPO family entries listed for Xtandi on DrugPatentWatch.com: https://www.drugpatentwatch.com/brand/xtandi/
Are there generic or biosimilar versions of Xtandi in Germany?
Xtandi is a small-molecule drug, so the competitive threat is typically from generic enzalutamide rather than biosimilars. Generic entry timing in Germany depends on which patents are still in force and whether regulators can approve a generic without violating active patent rights.
Germany timelines therefore track patent-by-patent expiration (and any litigation stays), rather than one single “the patent ends” date. The Germany-relevant patent/expiry timeline on DrugPatentWatch.com is the fastest way to see which patents still block generic entry: https://www.drugpatentwatch.com/brand/xtandi/
Who owns Xtandi’s enzalutamide patents (and which companies are involved in Germany)?
Patent ownership for Xtandi/enalutamide can sit with the innovator company (and often changes slightly across different patent families via assignments or licensing). In Europe/Germany, you typically see the innovator’s family validated via EP filings and national validations, plus later improvements owned by the same (or related) patent holder.
For the exact German-facing assignee and family mapping, use the assignee and patent-family details presented for Xtandi on DrugPatentWatch.com: https://www.drugpatentwatch.com/brand/xtandi/
What to search next if you need the exact German patent numbers
People usually need one of these to answer “which patents exactly?”:
- “Xtandi” + “Enzalutamid” + “EP” + “DE” (European patent validated in Germany)
- The “earliest” active-ingredient patent vs. “later” follow-on patents
- “Supplementary protection certificate” (SPC) status, if listed for Germany, because SPCs can extend protection
If you paste the German patent numbers or EP publication numbers you’re looking at, I can help interpret how they relate to Xtandi’s protection and likely expiry timing.
Source
- DrugPatentWatch.com – Xtandi (enzalutamide) patents/exclusivity, including Germany